Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Articaine is a **small-molecule amide local anesthetic** used primarily for local and regional anesthesia, especially in dentistry, and is also being developed in a topical ophthalmic formulation. Pharmacologically, it blocks **voltage-gated sodium channels** in peripheral nerves, preventing initiation and propagation of action potentials and thereby producing reversible loss of sensation. Unlike many other amide anesthetics, articaine contains a thiophene ring and an additional ester group, which contributes to rapid tissue penetration and hydrolysis. Publicly verifiable development activity includes American Genomics' **AG-920**, an articaine sterile topical ophthalmic solution studied in Phase 1 and Phase 3 trials for ocular surface anesthesia, while marketed dental products include articaine hydrochloride formulations, commonly combined with epinephrine for infiltration or nerve block anesthesia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on articaine.